Rigel Pharmaceuticals, Inc. provided revenue guidance for the fourth quarter of 2022. For the quarter, the company expected to report total revenue of approximately $51.3 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9314 USD | +2.63% | -2.46% | -35.77% |
07/05 | Transcript : Rigel Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
07/05 | Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q1 Revenue $29.5M, vs. Street Est of $31.5M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.77% | 16Cr | |
+9.83% | 12TCr | |
+10.80% | 11TCr | |
-10.84% | 2.34TCr | |
-1.69% | 2.21TCr | |
-10.23% | 1.83TCr | |
-41.92% | 1.66TCr | |
-15.11% | 1.6TCr | |
+6.62% | 1.4TCr | |
+17.53% | 1.17TCr |
- Stock Market
- Equities
- RIGL Stock
- News Rigel Pharmaceuticals, Inc.
- Rigel Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022